The estimated Net Worth of John R Stuelpnagel is at least $53.2 Million dollars as of 5 June 2023. Mr. Stuelpnagel owns over 10,000 units of 10x Genomics stock worth over $7,375,566 and over the last 21 years he sold TXG stock worth over $45,794,083. In addition, he makes $31,957 as Independent Chairman of the Board at 10x Genomics.
John has made over 92 trades of the 10x Genomics stock since 2004, according to the Form 4 filled with the SEC. Most recently he sold 10,000 units of TXG stock worth $548,900 on 5 June 2023.
The largest trade he's ever made was selling 30,000 units of 10x Genomics stock on 7 June 2006 worth over $805,200. On average, John trades about 6,854 units every 67 days since 2004. As of 5 June 2023 he still owns at least 333,736 units of 10x Genomics stock.
You can see the complete history of Mr. Stuelpnagel stock trades at the bottom of the page.
John R. Stuelpnagel serves as Independent Chairman of the Board of the Company. He has been Chairman of our board of directors since August 2013. In addition, Dr. Stuelpnagel co-founded and was Executive Chairman of Ariosa Diagnostics from October 2009 to January 2015 when that company was sold to Roche. He was also the Chairman of Sequenta from November 2010 to January 2015 when that company was merged with Adaptive Biotechnologies where he continued as a member of their board of directors from January 2015 to November 2017. Dr. Stuelpnagel has served as the Chairman of Fabric Genomics since August 2009, the Chairman of Inscripta since April 2017, the Chairman of Element Biosciences since September 2017, and a member of the board of directors for Encoded Therapeutics since May 2017. Previously, Dr. Stuelpnagel co-founded Illumina in 1998 where he worked until March 2009. Prior to Illumina, Dr. Stuelpnagel was an associate at CW Group from 1997 to 1998. Dr. Stuelpnagel received his B.S. in Biochemistry and his Doctorate in Veterinary Medicine from the University of California, Davis and his M.B.A. from the University of California, Los Angeles.
As the Independent Chairman of the Board of 10x Genomics, the total compensation of John Stuelpnagel at 10x Genomics is $31,957. There are 12 executives at 10x Genomics getting paid more, with Serge Saxonov having the highest compensation of $2,362,960.
John Stuelpnagel is 62, he's been the Independent Chairman of the Board of 10x Genomics since 2013. There are no older and 16 younger executives at 10x Genomics.
John's mailing address filed with the SEC is C/O 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON, CA, 94588.
Over the last 5 years, insiders at 10x Genomics have traded over $629,686,183 worth of 10x Genomics stock and bought 487,816 units worth $19,025,295 . The most active insiders traders include Bryan E Roberts, Capital Management I, Llc F... und Benjamin J. Hindson. On average, 10x Genomics executives and independent directors trade stock every 8 days with the average trade being worth of $1,002,346. The most recent stock trade was executed by Serge Saxonov on 22 August 2024, trading 6,749 units of TXG stock currently worth $152,055.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
10x Genomics executives and other stock owners filed with the SEC include: